News
New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...
Celcuity Inc. (NASDAQ:CELC) stock surged on Monday after the company reported topline results from the PIK3CA wild-type ...
We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on ...
3d
InvestorsHub on MSNCelcuity Shares Double After Landmark Breast Cancer Drug Trial Results
Celcuity Inc. (NASDAQ:CELC) saw its stock soar by more than 100% on Monday following the release of groundbreaking Phase 3 ...
A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...
Celcuity shares skyrocketed to an all-time high when the biotech reported positive results from a Phase 3 trial of its ...
At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...
US clinical-stage oncology focused biotech Celcuity saw its shares skyrocket 180% to $38.59 in early trading as it announced ...
All patients received prior palbociclib: 14 patients with an AI, 6 patients with fulvestrant, and 1 patient received palbociclib with an AI and then with fulvestrant. Of the 21 patients, 17 were ...
Fulvestrant is an analog of 17B-estradiol that binds the estrogen receptor (ER) with a similar affinity to the parent molecule. 3 However, because of the alkinylsulphinyl side chain in the 7-alpha ...
Fulvestrant was as effective as anastrozole in terms of time to progression (TTP) (hazard ratio, 0.92; 95% confidence interval [CI], 0.74-1.14; P =.43). Median TTP was 5.4 months with fulvestrant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results